Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
New England Journal of Medicine · 05.06.2025 · 392 (21) · 2089-2099
DOI: 10.1056/nejmoa2413258 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.06.2025. Verfasst von Arun J Sanyal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1244-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond.
- Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London.
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
- Novo Nordisk, Bagsværd, Denmark.
- Department of Medical Sciences, University of Turin, Turin, Italy.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago.
ORCID-Profile: Mette Skalshøi Kjær
Förderung
- Novo Nordisk A/S
Zitieren
APA
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., Ratziu, V., & ESSENCE Study Group (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine, 392(21), 2089-2099. https://doi.org/10.1056/nejmoa2413258
Vancouver
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025;392(21):2089-2099. doi:10.1056/nejmoa2413258
BibTeX
@article{Sanyal2025,
author = {Sanyal, Arun J and Newsome, Philip N and Kliers, Iris and Østergaard, Laura Harms and Long, Michelle T and Kjær, Mette Skalshøi and Cali, Anna M G and Bugianesi, Elisabetta and Rinella, Mary E and Roden, Michael and Ratziu, Vlad and ESSENCE Study Group, ESSENCE Study Group},
title = {Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {21},
pages = {2089--2099},
doi = {10.1056/nejmoa2413258}
}
EUVIMED